Aerosolized fluoroquinolones and uses thereof
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-031/00
A61K-031/44
A61K-031/4412
A61K-033/00
A61K-033/14
A61K-033/26
A61K-033/30
A01N-025/00
A01N-025/02
A01N-025/06
A01N-059/08
출원번호
US-0604340
(2009-10-22)
등록번호
US-8546423
(2013-10-01)
발명자
/ 주소
Surber, Mark W.
Bostian, Keith A.
Dudley, Michael N.
Lomovskaya, Olga
Griffith, David C.
출원인 / 주소
MPEX Pharmaceuticals, Inc.
대리인 / 주소
Knobbe, Martens, Olson & Bear, LLP
인용정보
피인용 횟수 :
5인용 특허 :
149
초록▼
Disclosed herein are formulations of fluoroquinolones suitable for aerosolization and use of such formulations for aerosol administration of fluoroquinolone antimicrobials for the treatment of pulmonary bacterial infections. In particular, inhaled levofloxacin specifically formulated and delivered f
Disclosed herein are formulations of fluoroquinolones suitable for aerosolization and use of such formulations for aerosol administration of fluoroquinolone antimicrobials for the treatment of pulmonary bacterial infections. In particular, inhaled levofloxacin specifically formulated and delivered for bacterial infections of the lungs is described. Methods include inhalation protocols and manufacturing procedures for production and use of the compositions described.
대표청구항▼
1. A method of treating a bacterial lung infection, comprising administering an aerosol of a solution comprising levofloxacin or ofloxacin and a divalent or trivalent cation to a lung. 2. The method of claim 1, wherein the lung infection is caused by one or more of the following bacteria: Pseudomona
1. A method of treating a bacterial lung infection, comprising administering an aerosol of a solution comprising levofloxacin or ofloxacin and a divalent or trivalent cation to a lung. 2. The method of claim 1, wherein the lung infection is caused by one or more of the following bacteria: Pseudomonas aeruginosa, Pseudomonas fluorescens, Pseudomonas acidovorans, Pseudomonas alcaligenes, Pseudomonas putida, Stenotrophomonas maltophilia, Aeromonas hydrophilia, Escherichia coli, Citrobacter freundii, Salmonella typhimurium, Salmonella typhi, Salmonella paratyphi, Salmonella enteritidis, Shigella dysenteriae, Shigella flexneri, Shigella sonnei, Enterobacter cloacae, Enterobacter aerogenes, Klebsiella pneumoniae, Klebsiella oxytoca, Serratia marcescens, Morganella morganii, Proteus mirabilis, Proteus vulgaris, Providencia alcalifaciens, Providencia rettgeri, Providencia stuartii, Acinetobacter calcoaceticus, Acinetobacter haemolyticus, Yersinia enterocolitica, Yersinia pestis, Yersinia pseudotuberculosis, Yersinia intermedia, Bordetella pertussis, Bordetella parapertussis, Bordetella bronchiseptica, Haemophilus influenzae, Haemophilus parainfluenzae, Haemophilus haemolyticus, Haemophilus parahaemolyticus, Haemophilus ducreyi, Pasteurella multocida, Pasteurella haemolytica, Helicobacter pylori, Campylobacter fetus, Campylobacter jejuni, Campylobacter coli, Borrelia burgdorferi, Vibrio cholera, Vibrio parahaemolyticus, Legionella pneumophila, Listeria monocytogenes, Neisseria gonorrhoeae, Neisseria meningitidis, Burkholderia cepacia, Francisella tularensis, Kingella, and Moraxella. 3. The method of claim 1, wherein the lung infection is caused by one or more of the following bacteria: Pseudomonas aeruginosa, Stenotrophomonas maltophilia, Haemophilus influenzae, Burkholderia cepacia, and Moraxella. 4. The method of claim 1, wherein the lung infection is caused by a Burkholderia bacteria. 5. The method of claim 1, wherein the lung infection is associated with a bacterial pneumonia. 6. The method of claim 1, wherein the lung infection is caused by a gram-negative anaerobic bacteria. 7. The method of claim 1, wherein the lung infection is caused by one or more of the bacteria selected from the group consisting of Bacteroides fragilis, Bacteroides distasonis, Bacteroides 3452A homology group, Bacteroides vulgatus, Bacteroides ovalus, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides eggerthii, and Bacteroides splanchnicus. 8. The method of claim 1, wherein the lung infection is caused by a gram-positive bacteria. 9. The method of claim 1, wherein the lung infection is caused by one or more of the bacteria selected from the group consisting of Corynebacterium diphtherias, Corynebacterium ulcerans, Streptococcus pneumoniae, Streptococcus agalactiae, Streptococcus pyogenes, Streptococcus milleri; Streptococcus (Group G); Streptococcus (Group C/F); Enterococcus faecalis, Enterococcus faecium, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus saprophyticus, Staphylococcus intermedius, Staphylococcus hyicus subsp. hyicus, Staphylococcus haemolyticus, Staphylococcus hominis, and Staphylococcus saccharolyticus. 10. The method of claim 1, wherein the lung infection is caused by a gram-positive anaerobic bacteria. 11. The method of claim 1, wherein the lung infection is caused by one or more bacteria selected from the group consisting of Clostridium difficile, Clostridium perfringens, Clostridium tetini, and Clostridium botulinum. 12. The method of claim 1, wherein the lung infection is caused by an acid-fast bacteria. 13. The method of claim 1, wherein the lung infection is caused by a Mycobacterium bacteria. 14. The method of claim 13, wherein the lung infection is caused by one or more bacteria selected from the group consisting of Mycobacterium tuberculosis, Mycobacterium avium, Mycobacterium intracellulare, and Mycobacterium leprae. 15. The method of claim 1, wherein the lung infection is caused by an atypical bacteria. 16. The method of claim 1, wherein the lung infection is caused by one or more bacteria selected from the group consisting of Chlamydia pneumoniae and Mycoplasma pneumoniae. 17. The method of claim 1, wherein the solution comprises levofloxacin at a concentration from about 100 mM to about 625 mM and magnesium chloride at a concentration from about 125 mM to about 250 mM, has a pH from about 5.5 to about 6.5, and an osmolality from about 350 mOsmol/kg to about 750 mOsmol/kg. 18. The method of claim 1, wherein the aerosol has a mass median aerodynamic diameter from about 2 microns to about 5 microns with a geometric standard deviation less than or equal to about 2.5 microns. 19. The method of claim 1, wherein the aerosol has a mass median aerodynamic diameter from about 2.5 microns to about 4.5 microns with a geometric standard deviation less than or equal to about 1.8 microns. 20. The method of claim 1, wherein the aerosol has a mass median aerodynamic diameter from about 2.8 microns to about 4.3 microns with a geometric standard deviation less than or equal to about 2 microns. 21. The method of claim 1, comprising producing the aerosol with a vibrating mesh nebulizer. 22. The method of claim 21, wherein the aerosol has a mass median aerodynamic diameter from about 2 microns to about 5 microns with a geometric standard deviation less than or equal to about 2.5 microns. 23. The method of claim 21, wherein the aerosol has a mass median aerodynamic diameter from about 2.8 microns to about 4.3 microns with a geometric standard deviation less than or equal to about 2 microns. 24. The method of claim 21, wherein the aerosol has a mass median aerodynamic diameter from about 2.5 microns to about 4.5 microns with a geometric standard deviation less than or equal to about 1.8 microns. 25. The method of claim 1, wherein at least about 20 mg of levofloxacin or ofloxacin is administered to the lung. 26. The method of claim 1, wherein at least about 100 mg of levofloxacin or ofloxacin is administered to the lung. 27. The method of claim 1, wherein at least about 125 mg of levofloxacin or ofloxacin is administered to the lung. 28. The method of claim 1, wherein at least about 150 mg of levofloxacin or ofloxacin is administered to the lung. 29. The method of claim 1, wherein the aerosol is administered to the lung in less than about 10 minutes. 30. The method of claim 1, wherein the aerosol is administered to the lung in less than about 5 minutes. 31. The method of claim 1, wherein the aerosol is administered to the lung in less than about 3 minutes. 32. The method of claim 1, wherein the aerosol is administered to the lung in less than about 2 minutes. 33. The method of claim 1, further comprising the step of alternating the administration of said aerosol with administration of a second inhaled antimicrobial. 34. The method of claim 33, wherein the second inhaled antimicrobial is an aminoglycoside. 35. The method of claim 34, wherein the aminoglycoside is tobramycin. 36. The method of claim 33, wherein the second inhaled antimicrobial is a polymyxin. 37. The method of claim 36, wherein the polymyxin is colistin. 38. The method of claim 33, wherein the second inhaled antimicrobial is a monobactam. 39. The method of claim 38, wherein the monobactam is aztreonam. 40. The method of claim 1, comprising administering the aerosol once daily. 41. The method of claim 1, comprising administering the aerosol twice daily.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (149)
Schmidt, James N.; Engelbreth, Daniel; Blacker, Rick, Aerosol delivery apparatus with positive expiratory pressure capacity.
James N. Schmidt CA; Jerry Grychowski ; Daniel K. Engelbreth CA; Robert Morton CA; Martin P. Foley CA, Aerosol medication delivery apparatus and system.
Osbakken, Robert S.; Hale, Mary Anne; Leivo, Frederick T.; Munk, James D., Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis.
Gordeev, Mikhail F.; Patel, Dinesh V.; Barbachyn, Michael R.; Gage, James R., Antimicrobial quinolone derivatives and use of the same to treat bacterial infections.
Gordeev, Mikhail F.; Patel, Dinesh V.; Barbachyn, Michael R.; Gage, James R., Antimicrobial quinolone derivatives and use of the same to treat bacterial infections.
Hodson Peter D. (Trowell GB3) Baum Eric A. (Loughborough GB3) Smith David K. (Loughborough GB3) Kuepper Anton (Kaarst DEX) Wilby Matthew J. (Loughborough GB3), Breath actuated inhaler having an electromechanical priming mechanism.
Newell Robert E. (Pinner GB2) Rand Paul K. (Nitchin GB2) Fitzsimmons Robert A. (Barnard Castle GB2), Devices for administering medicaments to patients.
Casper, Robert A.; Leith, Frank A.; Gardner, David L.; Snow, John M.; Lyon, Zachary W.; Farrar, David S., Dry powder medicament inhalator having an inhalation-activated flow diverting means for triggering delivery of medicament.
Mulhauser Paul (New York NY) Karg Jeffrey (Waldwick NY) Foxen Thomas (Brooklyn NY) Brooks Christopher J. (Glen Head NY), Dry powder medicament inhalator having an inhalation-activated piston to aerosolize dose and deliver same.
Domagala John M. (Canton MI) Kiely John S. (Ann Arbor MI) Schroeder Mel C. (Dexter MI), Individual stereosiomers of 7-[3-(aminoalkyl)-1-pyrrolidinyl]-quinolones and naphthyridones as antibacterial agents.
Burns James S. (Darien CT) Marshak Daniel R. (Cold Spring Harbor NY), Inhalation device with a dose-timer, an actuator mechanism, and patient compliance monitoring means.
Ambrosio Thomas J. ; Ashley Charles R. ; Bilanin Alan J. ; Huck Charles M. ; Kaufman Andrew E. ; Kenyon David J. ; Manthena Srinivas ; Sochon Henry R. ; Wilkinson Ken ; Yang Tsong-Toh, Inhaler for powdered medications.
Hess Joseph,CHX ; Bo Hu,CHX ; Weber Raphael,CHX ; Ortega Isabel,CHX ; Barraud Cedric,CHX ; van der Schoot Bart,CHX ; de Rooij Nicolaas Frans,CHX ; de Heij Bas,CHX, Liquid droplet spray device for an inhaler suitable for respiratory therapies.
Zoltan Bart J. (Old Tappan NJ) Laube Beth L. (Baltimore MD) Adams ; III George K. (Baltimore MD) Bow Clark F. (Newton NJ) Devito Ralph J. (Stanhope NJ) Harrington Walter (Flanders NJ) Hoffman Louis S, Medication delivery system phase two.
Smith Adrian E. ; Burr John D. ; Etter Jeffery W. ; Axford George S. ; Lyons Shirley W. ; Platz Robert M., Method and apparatus for dispersion of dry powder medicaments.
Blineau Joseph (Rennes FRX) Pommier Daniel (Mordelles FRX) Thomas Claude (Chasne sur Illet FRX), Multiplex channels for continuous flow for numerical signal.
Nowacki Christopher (Arlington Heights IL) Brisson Alfred G. (Kildeer IL) Dela-Cruz Exequiel (Arlington Heights IL), Pediatric asthmatic medication inhaler.
Arnold Klaus (Ingelheim am Rhein DEX) Grass Peter (Ingelheim am Rhein DEX) Knecht Adolf (Freiburg DEX) Roos Robert (Ingelheim am Rhein DEX) Sluke Gerhard (Ingelheim am Rhein DEX) Thieme Herbet (Ingel, Powders for inhalation.
Knight Jack V. (Houston TX) Wilson ; Jr. Samuel Z. (Houston TX), Small particle aerosol generator for treatment of respiratory disease including the lungs.
Welsh, Michael J.; Zabner, Joseph, Use of xylitol to reduce ionic strength and activate endogenous antimicrobials for prevention and treatment of infections.
Griffith, David C.; Dudley, Michael N.; Surber, Mark W.; Bostian, Keith A.; Rodny, Olga, Aerosol fluoroquinolone formulations for improved pharmacokinetics.
Griffith, David C.; Dudley, Michael N.; Surber, Mark W.; Bostian, Keith A.; Rodny, Olga, Aerosol fluoroquinolone formulations for improved pharmacokinetics.
Griffith, David C.; Dudley, Michael N.; Surber, Mark W.; Bostian, Keith A.; Rodny, Olga, Aerosol fluoroquinolone formulations for improved pharmacokinetics.
Loutit, Jeffery S.; Morgan, Elizabeth E.; Dudley, Michael N.; Griffith, David C.; Lomovskaya, Olga, Use of aerosolized levofloxacin for treating cystic fibrosis.
Loutit, Jeffery S.; Morgan, Elizabeth E.; Dudley, Michael N.; Griffith, David C.; Lomovskaya, Olga, Use of aerosolized levofloxacin for treating cystic fibrosis.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.